Trials / Completed
CompletedNCT07050446
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
Multicentre, Randomized, Controlled, Double-blind, Parallel Design Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Vizol S DIGI EYE in the Adult Patient Population With Moderate to Severe Dry Eye Disease for up to 28 Days
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Jadran Galenski laboratorij d.d. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to severe evaporative DED after a treatment for 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vizol S DIGI EYE eye drops | 1 drop 4 times a day |
| DRUG | 0,9% saline solution, eye drops | 1 drop 4 times a day |
Timeline
- Start date
- 2024-03-20
- Primary completion
- 2024-08-23
- Completion
- 2024-11-02
- First posted
- 2025-07-03
- Last updated
- 2025-07-03
Locations
3 sites across 1 country: Serbia
Source: ClinicalTrials.gov record NCT07050446. Inclusion in this directory is not an endorsement.